Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine

[1]  A. Falini,et al.  Tumours , 2008, Neurological Sciences.

[2]  Gary D Bader,et al.  PRMT5 inhibition disrupts splicing and stemness in glioblastoma , 2021, Nature Communications.

[3]  W. Liu,et al.  MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. , 2021, Cancer cell.

[4]  R. DePinho,et al.  An Enolase Inhibitor for the Targeted Treatment of ENO1-Deleted Cancers , 2020, Nature Metabolism.

[5]  Minoru Kanehisa,et al.  KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..

[6]  Wenzhi Sun,et al.  Using arterial–venous analysis to characterize cancer metabolic consumption in patients , 2020, Nature Communications.

[7]  Nicholas D. Adams,et al.  Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. , 2019, Cancer cell.

[8]  J. Locasale,et al.  Nutrient availability shapes methionine metabolism in p16/MTAP-deleted cells , 2019, Science Advances.

[9]  T. Ackermann,et al.  Cell Culture Medium Formulation and Its Implications in Cancer Metabolism. , 2019, Trends in cancer.

[10]  G. G. Galli,et al.  The landscape of cancer cell line metabolism , 2019, Nature Medicine.

[11]  M. Zampieri,et al.  Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism , 2019, Nature Communications.

[12]  G. Finocchiaro,et al.  The landscape of the mesenchymal signature in brain tumours , 2019, Brain : a journal of neurology.

[13]  Xiaobing Shi,et al.  PRMT1 loss sensitizes cells to PRMT5 inhibition , 2019, Nucleic acids research.

[14]  Sung-Liang Yu,et al.  Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma , 2019, Signal Transduction and Targeted Therapy.

[15]  Gabriela Kalna,et al.  Improving the metabolic fidelity of cancer models with a physiological cell culture medium , 2019, Science Advances.

[16]  I. Nakano,et al.  Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma , 2018, Neuro-oncology.

[17]  T. Köcher,et al.  RIOK1 kinase activity is required for cell survival irrespective of MTAP status , 2018, Oncotarget.

[18]  A. Riccio,et al.  H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. , 2017, Cancer cell.

[19]  Steven D Chang,et al.  Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.

[20]  Y. Lotan,et al.  Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer , 2017, Cancer medicine.

[21]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[22]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[23]  R. DePinho,et al.  SF2312 is a natural phosphonate inhibitor of Enolase , 2016, Nature chemical biology.

[24]  A. Kernytsky,et al.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. , 2016, Cell reports.

[25]  T. Golub,et al.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.

[26]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[27]  Chris Sander,et al.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.

[28]  R. DePinho,et al.  Collateral Lethality: A new therapeutic strategy in oncology. , 2015, Trends in cancer.

[29]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[30]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[31]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[32]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[33]  Annette M Molinaro,et al.  Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy , 2014, NMR in biomedicine.

[34]  Jing Fan,et al.  Quantitation of cellular metabolic fluxes of methionine. , 2014, Analytical chemistry.

[35]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[36]  Wolfram Gronwald,et al.  Distinct metabolic differences between various human cancer and primary cells , 2013, Electrophoresis.

[37]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[38]  K. Kohn,et al.  268 CellMiner: a Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set , 2012 .

[39]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[40]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[41]  Mauro Delorenzi,et al.  DNA fingerprinting of glioma cell lines and considerations on similarity measurements. , 2012, Neuro-oncology.

[42]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[43]  J. Asara,et al.  A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue , 2012, Nature Protocols.

[44]  L. Cantley,et al.  Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma* , 2012, Molecular & Cellular Proteomics.

[45]  Yu-Jie Hu,et al.  Versatility of PRMT5-induced methylation in growth control and development. , 2011, Trends in biochemical sciences.

[46]  Helmut Kettenmann,et al.  The brain tumor microenvironment , 2011, Glia.

[47]  Gang Su,et al.  Integrated metabolome and transcriptome analysis of the NCI60 dataset , 2011, BMC Bioinformatics.

[48]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[49]  Darell D. Bigner,et al.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes , 2010, Oncotarget.

[50]  Peter J. Oefner,et al.  Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies. , 2010, Journal of chromatography. A.

[51]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[52]  P. Oefner,et al.  Direct and tumor microenvironment mediated influences of 5′‐deoxy‐5′‐(methylthio)adenosine on tumor progression of malignant melanoma , 2009, Journal of cellular biochemistry.

[53]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[54]  P. Kehrli,et al.  Toward improved grading of malignancy in oligodendrogliomas using metabolomics , 2008, Magnetic resonance in medicine.

[55]  Masakazu Toi,et al.  Angiogenic inhibitors: a new therapeutic strategy in oncology , 2005, Nature Clinical Practice Oncology.

[56]  R. Hruban,et al.  Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion , 2005, Modern Pathology.

[57]  M. Mann,et al.  A Novel WD Repeat Protein Component of the Methylosome Binds Sm Proteins* , 2002, The Journal of Biological Chemistry.

[58]  Juri Rappsilber,et al.  The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins , 2001, Molecular and Cellular Biology.

[59]  G. Fuller,et al.  An implantable guide-screw system for brain tumor studies in small animals. , 2000, Journal of neurosurgery.

[60]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[61]  M. Diccianni,et al.  Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. , 1996, Blood.

[62]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[63]  C. Betsholtz,et al.  Evidence for progressional changes in the human malignant glioma line U-343 MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor. , 1987, Cancer research.

[64]  D. Carson,et al.  Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells. , 1984, Biochemical and biophysical research communications.

[65]  M. Riscoe,et al.  5-Methylthioribose. Its effects and function in mammalian cells. , 1984, The Journal of biological chemistry.

[66]  N. Kamatani,et al.  Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. , 1980, Cancer research.

[67]  S. Eschrich,et al.  Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism , 2012 .

[68]  A. Børresen-Dale,et al.  Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.

[69]  P. Oefner,et al.  Gastrointestinal , Hepatobiliary , and Pancreatic Pathology Down-Regulation of Methylthioadenosine Phosphorylase ( MTAP ) Induces Progression of Hepatocellular Carcinoma via Accumulation of 5 =-Deoxy-5 =-Methylthioadenosine ( MTA ) , 2011 .

[70]  T. Savarese,et al.  Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.